Literature DB >> 10879547

Assessing the executive function abilities of adults with neurogenic communication disorders.

L L Murray1, A E Ramage.   

Abstract

Whereas it is known that executive function abilities are often impaired in clients having neurogenic communication disorders, few assessments of this cognitive domain are available that consider the speech and language deficits of this population. This article provides an overview of current procedures for assessing executive functions including a discussion of team approaches to assessment, a review of currently available neuropsychological and functional tests of executive function abilities, as well as a critique of those assessment procedures. In addition, suggestions are provided for how best to use or modify appropriately current tests of executive functioning for clients having acquired speech and language disorders as a result of brain damage.

Entities:  

Mesh:

Year:  2000        PMID: 10879547     DOI: 10.1055/s-2000-7562

Source DB:  PubMed          Journal:  Semin Speech Lang        ISSN: 0734-0478            Impact factor:   1.761


  3 in total

1.  Effects of working memory load on processing of sounds and meanings of words in aphasia.

Authors:  Nadine Martin; Francine Kohen; Michelene Kalinyak-Fliszar; Anna Soveri; Matti Laine
Journal:  Aphasiology       Date:  2012-02-22       Impact factor: 2.773

2.  C-Speak Aphasia alternative communication program for people with severe aphasia: importance of executive functioning and semantic knowledge.

Authors:  Marjorie Nicholas; Michele P Sinotte; Nancy Helm-Estabrooks
Journal:  Neuropsychol Rehabil       Date:  2011-06-01       Impact factor: 2.868

3.  An fMRI paradigm based on Williams inhibition test to study the neural substrates of attention and inhibitory control.

Authors:  Artemisa R Dores; Fernando Barbosa; Irene P Carvalho; Isabel Almeida; Sandra Guerreiro; Benedita Martins da Rocha; Gil Cunha; Miguel Castelo Branco; Liliana de Sousa; Alexandre Castro Caldas
Journal:  Neurol Sci       Date:  2017-09-30       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.